Biopharma company GSK (LSE: GSK) (NYSE: GSK) announced on Monday that it has secured Fast Track designation from the US FDA for bepirovirsen, an investigational antisense oligonucleotide (ASO) targeting chronic hepatitis B (CHB).
The designation expedites drug development for serious conditions with unmet medical needs. Bepirovirsen's potential was supported by phase IIb trials B-Clear and B-Sure, with ongoing phase III program B-Well.
CHB affects nearly 300 million people globally, with current treatments offering a less than 2-8% functional cure rate.
Bepirovirsen is in phase III development, showing promise for a clinically meaningful functional cure response when combined with oral nucleoside/nucleotide analogues.
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI